623 related articles for article (PubMed ID: 12086291)
1. Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors.
Peura DA
Cleve Clin J Med; 2002; 69 Suppl 1():SI31-9. PubMed ID: 12086291
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling.
Brown TJ; Hooper L; Elliott RA; Payne K; Webb R; Roberts C; Rostom A; Symmons D
Health Technol Assess; 2006 Oct; 10(38):iii-iv, xi-xiii, 1-183. PubMed ID: 17018227
[TBL] [Abstract][Full Text] [Related]
3. Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy.
Fendrick AM
Cleve Clin J Med; 2002; 69 Suppl 1():SI59-64. PubMed ID: 12086296
[TBL] [Abstract][Full Text] [Related]
4. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
[TBL] [Abstract][Full Text] [Related]
5. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors.
Laine L
Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):25-32. PubMed ID: 12528071
[TBL] [Abstract][Full Text] [Related]
6. Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors.
Scheiman JM
Cleve Clin J Med; 2002; 69 Suppl 1():SI40-6. PubMed ID: 12086292
[TBL] [Abstract][Full Text] [Related]
7. An evidence-based evaluation of the gastrointestinal safety of coxibs.
Bombardier C
Am J Cardiol; 2002 Mar; 89(6A):3D-9D. PubMed ID: 11909555
[TBL] [Abstract][Full Text] [Related]
8. [Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications].
;
Zhonghua Nei Ke Za Zhi; 2017 Jan; 56(1):81-85. PubMed ID: 28056333
[TBL] [Abstract][Full Text] [Related]
9. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
Hochberg MC
Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
[TBL] [Abstract][Full Text] [Related]
11. Gastrointestinal safety of selective COX-2 inhibitors.
Hawkey CJ; Skelly MM
Curr Pharm Des; 2002; 8(12):1077-89. PubMed ID: 11945152
[TBL] [Abstract][Full Text] [Related]
12. Current perspective on the cardiovascular effects of coxibs.
Konstam MA; Weir MR
Cleve Clin J Med; 2002; 69 Suppl 1():SI47-52. PubMed ID: 12086293
[TBL] [Abstract][Full Text] [Related]
13. Gastroduodenal safety of cyclooxygenase-2 inhibitors.
Scheiman JM
Curr Pharm Des; 2003; 9(27):2197-206. PubMed ID: 14529400
[TBL] [Abstract][Full Text] [Related]
14. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review.
Hooper L; Brown TJ; Elliott R; Payne K; Roberts C; Symmons D
BMJ; 2004 Oct; 329(7472):948. PubMed ID: 15475342
[TBL] [Abstract][Full Text] [Related]
15. COX-2 inhibitors vs. NSAIDs in gastrointestinal damage and prevention.
Ballinger A; Smith G
Expert Opin Pharmacother; 2001 Jan; 2(1):31-40. PubMed ID: 11336566
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.
Watson DJ; Harper SE; Zhao PL; Quan H; Bolognese JA; Simon TJ
Arch Intern Med; 2000 Oct; 160(19):2998-3003. PubMed ID: 11041909
[TBL] [Abstract][Full Text] [Related]
17. Gastro-duodenal protection in an era of cyclo-oxygenase-2-selective nonsteroidal anti-inflammatory drugs.
Naesdal J; Wilson I
Eur J Gastroenterol Hepatol; 2001 Dec; 13(12):1401-6. PubMed ID: 11742186
[TBL] [Abstract][Full Text] [Related]
18. From prostaglandin replacement to specific COX-2 inhibition: a critical appraisal.
Kremer J
J Rheumatol Suppl; 2000 Oct; 60():9-12. PubMed ID: 11032096
[TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase-2 inhibition and side-effects of non-steroidal anti-inflammatory drugs in the gastrointestinal tract.
Meyer-Kirchrath J; Schrör K
Curr Med Chem; 2000 Nov; 7(11):1121-9. PubMed ID: 11032962
[TBL] [Abstract][Full Text] [Related]
20. COX-2-selective inhibitors (COXIBs): gastrointestinal safety.
Pronai L; Hritz I; Molnar B; Herszenyi L; Tulassay Z
Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):23-30. PubMed ID: 14552701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
